Revenue Growth (YoY)
Higher than 13% of Healthcare sector peers
Updated 166h ago
Sector Performance
13th percentileNTLA
-9.5%
Sector Median
6.2%
Sector Avg
3.8%
Deep Analysis
Intellia Therapeutics, Inc. (NTLA) has a Revenue Growth (YoY) of -9.5% as of June 2026.
This places NTLA in the 13th percentile of the Healthcare sector, which has a median Revenue Growth (YoY) of 6.2% and a sector average of 3.8%. NTLA's Revenue Growth (YoY) is 253.2% below the sector median, a significant divergence that warrants closer examination. In context: Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
Frequently Asked Questions
What does the Revenue Growth (YoY) tell investors about NTLA?
Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
How is the Revenue Growth (YoY) calculated?
Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.
How does NTLA's Revenue Growth (YoY) compare to its sector?
NTLA's Revenue Growth (YoY) of -9.5% compares to a Healthcare sector median of 6.2%, placing it in the 13th percentile.
Who are NTLA's closest peers by Revenue Growth (YoY)?
The closest Healthcare peers by Revenue Growth (YoY) include: TMO (6.2%), AMGN (5.8%), CPRX (5.6%), HIMS (3.8%), BAX (2.9%).
The Formula
(Revenue_t - Revenue_t-4) / Revenue_t-4
Why It Matters
Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
Master NTLA's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full NTLA research report →NTLA
-9.5%
Sector Median
6.2%
Sector Avg
3.8%
How NTLA's Revenue Growth (YoY) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.